ULTIMA HORA

COVID 19 SOLICITUD AYUDA ESTUDIO EPIDEMIOLOGICO

Queridos amigos, familia, colegas

En este difícil momento del brote de COVID-19, sabemos que muchas personas están sufriendo emocional y mentalmente. Por ello, la Fundación Cerebro y Mente está llevando a cabo un estudio para determinar cómo este brote afecta a los síntomas de ansiedad y depresión en la población española (los infectados, los no infectados o los no probados). Un mes después de que se hayan levantado las restricciones de aislamiento, volveremos a evaluar estos síntomas, para ver si han mejorado. Les invitamos a ayudarnos con este importante estudio. Es importante que entendamos cómo la pandemia y el aislamiento social influyen en la salud mental. Queremos ver qué factores ayudan a las personas a sobrellevar mejor la situación y qué factores hacen que las personas sean más susceptibles de desarrollar ansiedad y síntomas depresivos. Esta información nos ayudará a desarrollar estrategias de tratamiento para después del COVID-19. También nos proporcionará pautas para la atención de la salud mental durante futuras pandemias. Por favor, envíen el enlace al mayor número de personas posible y mantengámonos unidos y ayudemos a mejorar la salud mental en España.

FORMULARIO

Gracias

Últimas Publicaciones

SALUD MENTAL EN LAS PERSONAS MAYORES

libro personas mayores

Una Guía Práctica

Versión Española

Mayo 2019

STRATEGIES FOR STUDYING BRAIN DISORDERS

Vol.9 Sistema Dopaminérgico y Trastornos Psiquiátricos

Vol.10 Staging Neuropsychiatric Disorders: Implications for Etiopathogenesis and Treatment

June 2013

ISBN: 978-1-4614-7263-6

Próximo curso

Madrid 11 y 12 de Noviembre de 2019

IX Curso Teórico-Práctico Intensivo de actualización en Terapia Electroconvulsiva

Más información

Último congreso

Fecha 20-21 Junio 2014

Relevance of Staging Psychotic disorders as a Paradigm-shift for understanding disease progression and stage-dependent treatment.

Más información

Publicaciones

Vol.5 Neurodegenerative Brain Disorders

Vol.5 Neurodegenerative Brain Disorders

December 2000

Editores: Tomás Palomo, Richard J. Beninger, Trevor Archer

Editorial: Editorial CYM, General Oráa, 47, 28006 MADRID

ISBN: 84-921848-2-5

Páginas: 813

Más información

Also found within the publications are contributions presented at the meeting held in Mojácar in 1999.

Tabla de contenidos

I. Neurotoxicity

  1. Neurotoxicity And Neurodegeneration: Implications For Neuropsychiatric Disorders. Tomás Palomo, Khem H Jhamandas, Richard J Beninger and Trevor Archer.
  2. Drug Addiction: Functional Neurotoxicity Of The Brain Reward Systems. F Weiss and GF Koob.
  3. Cytokine Effects on Oligodendrocytes: Implications for the Pathogenesis of Multiple Sclerosis. Eduardo Molina-Holgado, José Miguel Vela, Angel Luis Arévalo Martín, Sergio Ortiz and Carmen Guaza.
  4. Effects Of Prenatal Exposure To Cocaine On The Developing Brain: Anatomical, Chemical, Physiological And Behavioural Consequences. JA Harvey, AG Romano, M Gabriel, K Simansky, W Du, VJ Aloyo, and E Friedman.
  5. The Developing Cholinergic System as Target for Environmental Toxicants, Nicotine and Polychlorinated Biphenyls (Pcbs): Implications for Neurotoxicological Processes in Mice. P Eriksson, E Ankarberg, H Viberg and A Fredriksson.
  6. Oxidative Neuropathology And Putative Chemical Entities For Alzheimer’s Disease: Neuroprotective Effects Of Salen-Manganese Catalytic Anti-Oxidants. H Thomas Rupniak, Ken A Joy, Charlotte Atkin, Gill Brown , Julie C Barnes, Susan R Doctrow, Bernard Malfroy, Tony Wong , Ian K Anderson , Chris R Molloy, Gary I Mills, and Peter Soden.
  7. What Can Go Wrong When Memory Fails: The Main Biochemical Events Underlying Consolidation And Retrieval In Rats. Iván Izquierdo, João Quevedo, Luciana A Izquierdo, Monica RM Vianna, Germán Szapiro, Daniela M Barros, Rafael Roesler, Mariana Alonso, Roger Walz and Jorge H Medina.
  8. Neuroimaging Studies On Neurodegeneration In Schizophrenia. V Molina, S Reig, J Sanz, C Benito, M Desco, F Collazos, F.Artaloytia, M Martín-Loeches, F Sarramea, R Luque, R Montz, C Arango, T Palomo.
  9. Neurotoxicological Processes In Schizophrenia. Nuri B Farber, John W Newcomer and John W Olney.
  10. Functional Expressions of Noradrenergic Receptor Changes Following Denervation with DSP4: Interactive and Parametric Effects of Clonidine. Trevor Archer, Tomás Palomo and Anders Fredriksson.

II. Neurodegeneration

  1. Neurodegenerative Diseases Of The Brain: Genetic And Environmental Factors. Tomás Palomo, Richard J Beninger, Khem Jhamandas and Trevor Archer.
  2. Neurodegenerative Overlap Syndrome: Definition And Aetiology. Ryan J Uitti and Zbigniew K Wszolek.
  3. Hereditary Versus Environmental Causes for Neurodegeneration. Donald B Calne.
  4. Huntington Disease: A Model Excitotoxic Chronic Neurodegeneration. Terence Bazzett and Roger L Albin.
  5. Epidemiology of Alzheimer's Disease: Implications for Neurodegeneration. A Lobo, P Saz, G Marcos, S Aznar, and the ZARADEMP Workgroup.
  6. Neurotrophin Signalling in Alzheimer's Disease: Implications in Therapeutic Strategies. Isidro Ferrer.
  7. Cognitive Effects of Neurotoxic Lesions of the Nucleus Basalis Magnocellularis in Rats: Differential Roles for Corticopetal versus Amygdalopetal Projections. Richard J Beninger, Hans C Dringenberg, Roland J Boegman, and Khem Jhamandas.
  8. Glutamate Based Treatments for Schizophrenia. Bita Moghaddam.
  9. Neural Adaptability to Target Removal in Motor and Premotor Systems of Adult Mammals. José M Delgado-García, Agnès Gruart and Rosa R de la Cruz.
  10. Long Term Neurodevelopmental and Behavioral Effects of Perinatal Life Events in Rats. Muriel Koehl, Valérie Lemaire, Monique Vallée, Nora Abrous, Pier Vincenzo Piazza, Willy Mayo, Stefania Maccari and Michel Le Moal.
  11. Role of the Endogenous Cannabinoid System as a Modulator of Dopamine Transmission: Implications for Parkinson's Disease and Schizophrenia. Fernando Rodríguez de Fonseca, Miguel A Gorriti, Ainhoa Bilbao, Leticia Escuredo, Luis Miguel García-Segura, Daniele Piomelli and Miguel Navarro.
  12. Neurotoxicity Of Methamphetamine And Methylenedioxymethamphetamine. LS Seiden, R Lew and JE Malberg.
  13. Experimental Studies On 3,4- Methylenedioxymethamphetamine (MDMA, “Ecstasy”) And Its Potential To Damage Brain Serotonin Neurons. George A Ricaurte and Una D McCann.
  14. The Effect of Prenatal Cocaine Exposure on the Stress Response of Adult Mice. Cleopatra S Planeta, Jennifer Berliner, Andrew Russ, and Barry E Kosofsky.
  15. Neurofunctional Deficits in Mice Induced by Postnatal Iron Exposure: Dose, Time and MPTP Interactions. A Fredricksson, N Schröder, T Archer.

III. Neuroprotection

  1. Protective And Restorative Strategies In The Neurodegenerative Disorders. Tomás Palomo, Richard J Beninger, Khem Jhamandas, Richard M Kostrzewa, M Flint Beal and Trevor Archer.
  2. Prospects For Redox-Based Therapy In Neurodegenerative Diseases. Avi L Friedlich and M Flint Beal.
  3. Neuroprotective and Symptomatological Action of Memantine Relevant for Alzheimer's Disease – an Unified Hypothesis on the Mechanism of Action. W Danysz, CG Parsons, HJ Möbius, A Stöffler and G Quack.
  4. Excitotoxicity of Quinolinic Acid: Modulation by Endogenous Antagonists. KH Jhamandas, RJ Boegman, RJ Beninger, AF Miranda and KA Lipic.
  5. Death and Neuroprotection of Retinal Ganglion Cells after Different Types of Injury .Manuel Vidal-Sanz, Maria Lafuente, Paloma Sobrado-Calvo, Inmaculada Sellés-Navarro, Elena Rodríguez, Sergio Mayor-Torroglosa and María P Villegas-Pérez
  6. Neuroprotective strategies in Parkinson's Disease: Protection against progressive nigral damage induced by free radicals. Chuang Chin Chiueh, Sang Yong Lee, Tsugunobu Andoh, Andrew Ryan Lai, Edgar Lai and Gopal Krishna.
  7. Strategies for the Protection of Dopaminergic Neurons against Neurotoxicity. Manfred Gerlach, Kay L Double, Moussa BH Youdim, Peter Riederer.
  8. Restoration And Putative Protection Of MPTP-Induced Functional Deficits .Trevor Archer and Anders Fredriksson
  9. Neuroprotection in Alzheimer's Disease: New Strategies for Treatment. Agneta Nordberg.
  10. Neurotrophic Factors in Neurodegenerative Disorders: Model of Parkinson's Disease. Justo Garcia de Yebenes and Maria Angeles Mena.
  11. The Putative Neuroprotective Role of Dopamine Agonists in Parkinson’s Disease. Francisco Grandas.
  12. The Neuroprotectant Properties Of Glutamate Antagonists And Antiglutamatergic Drugs. Vera Pedersen and Werner J Schmidt.
  13. Review on Apoptosis Vs. Necrosis of Substantia Nigra Pars Compacta in Parkinson’s Disease. Richard M Kostrzewa.

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+